Authors
Loading...
This analysis examines market reactions to SFAS No. 2's requirements on R&D costs, suggesting minimal impact on management decisions.
Robert L. Vigeland (1981) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: